MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
Jessica M Nielsen, Christoph Pohl, Chris H Polman, Frederik Barkhof, Mark S Freedman, Gilles Edan, David H Miller, Lars Bauer, Rupert Sandbrink, Ludwig Kappos, Bernard M J Uitdehaag, Jessica M Nielsen, Christoph Pohl, Chris H Polman, Frederik Barkhof, Mark S Freedman, Gilles Edan, David H Miller, Lars Bauer, Rupert Sandbrink, Ludwig Kappos, Bernard M J Uitdehaag
Abstract
Background: To diagnose multiple sclerosis (MS), evidence for dissemination in space and time is required. There is no clear definition on how symptoms and signs of a patient indicate clinical dissemination in space. To provide a uniform approach on this subject, a clinical classification system was described recently differentiating patients with mono- and multifocal clinical presentation. Here we assess the predictive value of clinically defined dissemination in space at first presentation for time to clinically definite MS (CDMS).
Methods: Four hundred and sixty-eight patients with a first episode suggestive of MS were classified as clinically mono- or multifocal by two neurologists blinded to magnetic resonance imaging (MRI) results. These patients were part of the BENEFIT study in which 292 patients were randomized to interferon beta-1b (IFNB-1b) and 176 to placebo. By using Kaplan-Meier statistics the risk for CDMS was studied in mono- and multifocal patients of the placebo group, both with and without taking into account MRI measures of potential prognostic relevance.
Results: Time to CDMS was similar in monofocal and multifocal patients. In monofocal patients, the risk for CDMS over 2 years was significantly higher when >or= 9 T2 lesions or at least one Gd-enhancing lesion were present at the first event or 3 or 6 months after the first event. In patients with multifocal presentation, these MRI measures had no significant added value in predicting time to CDMS.
Conclusion: These data indicate that a carefully performed neurological assessment of symptoms and signs, combined with lesions on MRI, is important for defining the risk of conversion to CDMS.
Trial registration: The Benefit trial has been registered under NCT00185211 http://www.clinicaltrials.gov.
Figures
References
- Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126:770–782. doi: 10.1093/brain/awg081.
- Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:158–164. doi: 10.1056/NEJMoa011341.
- McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127. doi: 10.1002/ana.1032.
- Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703.
- Korteweg T, Tintore M, Uitdehaag B, et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 2006;5:221–227. doi: 10.1016/S1474-4422(06)70353-2.
- Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol. 2003;53:718–724. doi: 10.1002/ana.10551.
- Uitdehaag BM, Kappos L, Bauer L, et al. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler. 2005;11:227–231. doi: 10.1191/1352458505ms1149oa.
- Nielsen JM, Moraal B, Polman CH, et al. Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. Mult Scler. 2007;13:717–721. doi: 10.1177/1352458506074684.
- Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242–1249. doi: 10.1212/01.wnl.0000237641.33768.8d.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33:1444–1452.
- Polman C, Kappos L, Freedman MS, et al. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol. 2008;255:480–487. doi: 10.1007/s00415-007-0733-2.
- Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576–1582. doi: 10.1016/S0140-6736(00)04725-5.
- Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898–904. doi: 10.1056/NEJM200009283431301.
- Kinkel RP, O'Connor PW, kremenchutzky M. CHAMPS study reanalysis based on new clinically isolated syndrome classification criteria. Neurology. 2007;68 Abstract P04.070. Ref Type: Generic.
Source: PubMed